A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Inclusion Criteria:
- Participant has histologically confirmed FL (Grade 1, 2, 3a or classic FL) as assessed by local pathology. Adequate fresh tumor biopsy tissue or archived tumor biopsy from the latest relapse if available with corresponding pathology report for retrospective central pathology confirmation of relapse, is required. Evaluation from fine needle aspirate is not permitted.
- Relapsed or refractory disease: i) Relapsed FL is defined as relapse after an initial response of CR or PR to the most recent prior therapy.
ii) Refractory FL is defined as best response of SD or PD or a response that lasted less than 6 months to the most recent prior therapy.
Eastern Cooperative Oncology Group (ECOG) 0-2 (ECOG 3 authorized if it is due to lymphoma and not comorbidities).
Participant must have positron emission tomography (PET)-positive disease with at least one PET-positive lesion and measurable disease on cross section imaging by CT, as defined by Lugano classification.
Participants with an indication for anti-lymphoma treatment as per investigator assessment based on modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.
Participant has received at least 1 or more prior lines of systemic therapy with one line consisting of a combination including an anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab) and an alkylating agent (eg, cyclophosphamide, bendamustine). Prior treatment with radiation therapy does not count as a line of therapy for eligibility.
Lab parameters:
i) Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109 /L), ii) PLT count ≥ 75,000 cells/mm3 (75 x 109 /L) iii) Hb ≥ 7.5 g/dL
estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73m².
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN). In case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤ 5.0× ULN.
Serum total bilirubin ≤ 1.5 × ULN (corresponding to mild dysfunction as per National Cancer Institute Organ Dysfunction Working Group [NCI ODWG] criteria). In case of documented liver involvement by lymphoma, serum total bilirubin must be ≤ 3.0 × ULN (corresponding to moderate dysfunction as per NCI ODWG criteria). For cases of Gilberts syndrome, serum total bilirubin≤ 5.0 × ULN.
Adequate cardiac function for participants receiving anthracycline-based chemotherapy, defined as left ventricular ejection fraction (LVEF) ≥ 45% as assessed by echocardiogram (ECHO) as standard of care or multi-gated acquisition scan (MUGA).
Exclusion Criteria:
Clinical.Trials@bms.com8559073286
San Francisco, California 94143, United States
Marietta, Georgia 30060, United States
Fredericksburg, Virginia 22408, United States
Fuzhou Fujian, Fujian 350001, China
Wuhan, Hubei 430022, China
Sichuan, Sichuan 646000, China
Nantes, Loire-Atlantique 44093 Cedex 1, France
Toulouse, 31100, France
Dresden, 01307, Germany
Alexandroupoli, Anatolikí Makedonía Kai Thráki 681 00, Greece
Αthens, Attikí 11526, Greece
302132061702
New Delhi, National Capital Territory of Delhi 110029, India
Meldola, Emilia-Romagna 47014, Italy
Chuo-ku, Tokyo 104-0045, Japan
81335422511
Itabashiku, Tokyo 173-8610, Japan
+81-(0)3-3972-8111
Warsaw, Masovian Voivodeship 02-781, Poland
Istanbul- Fatih, Istanbul 34098, Turkey (Türkiye)
Cringleford, England NR4 7UY, United Kingdom
901-634-5546
907-257-9851
626-218-2405
415-238-1909
770-281-5100
000-000-0000
443-849-3051
601-261-1700
512-427-9400
903-579-9800
540-371-0079
540-982-0237
61288906352
85595000
41694645012243
+358 8 669 9500
13683398726
+8613719189172
15871725926
13520201279
+8613642138692
13752255454
+358 8 669 9500
+358 2 3130000
+358 9 4711
33557656511
+33675926918
33240083271
33320445713
33531156351
+491791098382
02312069011
+68411615358
+493617812476
036419327113
4937133344500
00493514400022
+302132041721
+390543739292
390282244080
+393470038656
390815903382
81527442141
81115632211
+81-79-294-2251
0552731111
81928520700
81926425230
81822413111
+31-20-5669111
+31887555878
+48793602210
+48602338290
48225462366
+34937231010
942292529Ext73188
34619249275
34963987649
0034958020013
01603 286286
01227 766877
01614 463000